Search

Your search keyword '"Marson, Domenico"' showing total 271 results
Start Over Author "Marson, Domenico"
271 results on '"Marson, Domenico"'

1. List of contributors

Author

Abdelhamid, Hani Nasser, primary, Abdel-Mottaleb, M.S.A., additional, Afify, Hisham G., additional, Ahmed, Heba A., additional, Ahmed, Naveed, additional, Alladio, Eugenio, additional, Alrefaie, Yamam, additional, Anis, Siti Nor Syairah, additional, Ashour, Kinana, additional, Askari, Vahid Reza, additional, Attia, Mohamed S., additional, Baradaran Rahimi, Vafa, additional, Barik, Binapani, additional, Bayan, Mohammad F., additional, Bindhani, Sabitri, additional, Birolo, Rebecca, additional, Biswal, Sangram Keshari, additional, Biswal, Snehanjana, additional, Bose, Anindya, additional, Bravetti, Federica, additional, Chandrasekaran, Balakumar, additional, Chierotti, Michele R., additional, Costa, Diana, additional, Danquah, Michael K., additional, Elmasry, Sohaila I., additional, El-Sayed, Sohaila G., additional, El-Sherbiny, Ibrahim M., additional, Faria, Rúben, additional, Galatou, Eleftheria, additional, Gamal, Osman, additional, Ghonem, M., additional, Gobetto, Roberto, additional, Hamza, Dalia A.M., additional, Hossam Eldin, Mariam, additional, Ibraheem, Umer, additional, Iosif, Elias, additional, Ishani, Naxtrshree, additional, Jeevanandam, Jaison, additional, Kadiman, Suhaini, additional, Karunanithi, Pooja B., additional, Khudzari, Ahmad Zahran Mohd, additional, Kobayashi, Takaomi, additional, Korsah, Maame A., additional, Laurini, Erik, additional, Lazim, Nurul Asmak Md, additional, Mansour, Nadia, additional, Mao, Shirui, additional, Marsin, Aishah Mohd, additional, Marson, Domenico, additional, Mehrotra, Sonal, additional, Mishra, Abhishek, additional, Mohamed, Aya, additional, Mohammad, Nagy N., additional, Mohapatra, Tapas Kumar, additional, Mourelatou, Elena A., additional, Muhamad, Ida Idayu, additional, Nakajima, Keita, additional, Narayan Sahoo, Rudra, additional, Nayak, Amit Kumar, additional, Neves, Ana R., additional, Noguchi, Sarara, additional, Omari, Derar M., additional, Pan, Sharadwata, additional, Pathak, Kamla, additional, Pathan, Hero Khan, additional, Petrou, Christos C., additional, Pricl, Sabrina, additional, Priyanka, Kumari, additional, Rabee, Maisara M., additional, Rehman, Asim ur, additional, Russi, Maria, additional, Sallam, ALSayyed A.N., additional, Sarigiannis, Yiannis, additional, Satapathy, Bhabani Sankar, additional, Sen, Kalyan Kumar, additional, Shaw, Tapan Kumar, additional, Sinha, Priyanka, additional, Vlasiou, Manos C., additional, Yahyazadeh, Roghayeh, additional, Zacharia, Lefteris, additional, and Zhang, Xin, additional

Published
2024
Full Text
View/download PDF

5. Contributors

Author

Abdel Aziz, Omar A., primary, Abo Dena, Ahmed S., additional, Ahad, Abdul, additional, Al-Jenoobi, Fahad I., additional, Al-Mohizea, Abdullah M., additional, Al Bawab, Abeer, additional, Albuquerque, Tânia, additional, Alshaer, Walhan, additional, Al Sulaibi, Mazen A.M., additional, Anis, Siti Nor Syairah, additional, Aqil, Mohd, additional, Arafa, Mona F., additional, Arafa, Kholoud, additional, Asrorov, Akmal M., additional, Bahrololoumi, Sara, additional, Banyikwa, Andrew T., additional, Benedini, Luciano, additional, Charoenying, Thapakorn, additional, Christensen, Jørn B., additional, Costa, Diana, additional, Dey, Sanjay, additional, Díaz-Torres, Roberto, additional, El-Sherbiny, Ibrahim M., additional, El Maghraby, Gamal M., additional, Eusébio, Dalinda, additional, Fahimirad, Shohreh, additional, Fahs, Duaa, additional, Fang, Yuefei, additional, Faria, Rúben, additional, Fatfat, Zaynab, additional, Fermeglia, Alice, additional, Ferreira, Miguel, additional, Gali-Muhtasib, Hala, additional, Gultekin, Hazal Ezgi, additional, Gupta, Dipak Kumar, additional, Haque, Shagufta, additional, Hasnain, Md Saquib, additional, Huang, Yongzhuo, additional, Ibrahim, Alaa, additional, Ilhan, Miray, additional, Jaber, Areej M., additional, Jha, Sajal Kumar, additional, Kabil, Mohamed Fawzi, additional, Kadiman, Suhaini, additional, Karam, Mia, additional, Karpuz, Merve, additional, Khater, Dima, additional, Kobayashi, Takaomi, additional, Kumar, Mohit, additional, Laurini, Erik, additional, Liew, Wen Ching, additional, López-Barrera, Laura Denise, additional, Maatouk, Batoul, additional, Mahmood, Syed, additional, Mandal, Uttam Kumar, additional, Mansour, Amira, additional, Marsin, Aishah Mohd, additional, Marson, Domenico, additional, Martinez Robinson, Karla G., additional, Mejlsøe, Søren Leth, additional, Mirzaakhmedov, Sharafitdin Ya., additional, Mohamed, Riham R., additional, Mohamed, Zeinab A., additional, Mubarak, Mohammad S., additional, Muhamad, Ida Idayu, additional, Nayak, Amit Kumar, additional, Neves, Ana R., additional, Nikazar, Sohrab, additional, Nsairat, Hamdi, additional, Odeh, Fadwa, additional, Oner, Ezgi, additional, Opanasopit, Praneet, additional, Patra, Chitta Ranjan, additional, Patrojanasophon, Prasopchai, additional, Pricl, Sabrina, additional, Ramírez-Noguera, Patricia, additional, Russi, Maria, additional, Sahini, Mtabazi G., additional, Sahoo, Nityananda, additional, Sankar, Muniappan, additional, Sousa, Ângela, additional, Sultan, Amal A., additional, Thakur, Pradeep Singh, additional, Tomić, Simonida Lj., additional, Tripathy, Sanchita, additional, Ventura, Cathy, additional, Wang, Huiyuan, additional, and Zamanzade, Zeynab, additional

Published
2023
Full Text
View/download PDF

7. Into the Groove: A Multitechnique Insight into the DNA–Vemurafenib Interaction.

Author

Cavalieri, Gabriele, Pison, Riccardo, Marson, Domenico, Laurini, Erik, and Pricl, Sabrina

Subjects
ISOTHERMAL titration calorimetry, MOLECULAR dynamics, MEASUREMENT of viscosity, NUCLEIC acids, CIRCULAR dichroism
Abstract

This study explores the interaction between Vemurafenib (VEM), a potent BRAF inhibitor, and calf thymus DNA (ctDNA) using a comprehensive array of biophysical and computational techniques. The primary objective is to understand the potential off-target effects of VEM on DNA, given its established role in melanoma therapy targeting the BRAF V600E mutation. The investigation employed methods such as ultraviolet–visible absorption spectroscopy, steady-state fluorescence, circular dichroism, isothermal titration calorimetry, and advanced molecular dynamics simulations. The results indicate that VEM interacts with DNA primarily through a minor groove-binding mechanism, causing minimal structural disruption to the DNA double helix. Viscosity measurements and melting temperature analyses further confirmed this non-intercalative mode of binding. Calorimetry data revealed an exothermic, thermodynamically favorable interaction between VEM and ctDNA, driven by both enthalpic and entropic factors. Finally, computer simulations identified the most probable binding site and mode of VEM within the minor groove of the nucleic acid, providing a molecular basis for the experimental findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. List of contributors

Author

Abdel-Mottaleb, M.S.A., primary, Aboulaghras, Sara, additional, Ahad, Abdul, additional, Akhtar, Naseem, additional, Al-Jenoobi, Fahad I., additional, Al-Mohizea, Abdullah M., additional, Aminabhavi, Tejraj M., additional, Andleeb, Rahat, additional, Ansari, Mohammed Tahir, additional, Aqil, Mohd., additional, Arafa, Kholoud K., additional, Ashraf, Asma, additional, Asrorov, Akmal M., additional, Atanase, Leonard I., additional, Attia, Mohamed S., additional, Aulic, Suzana, additional, Aydın, Hüsniye Hande, additional, Bajpai, A.K., additional, Bajpai, Jaya, additional, Balahbib, Abdelaali, additional, Banerjee, Sritoma, additional, Basu, Aalok, additional, Benedini, Luciano, additional, Bharti, Kanchan, additional, Bouyahya, Abdelhakim, additional, Bzainia, Amir, additional, Carvajal-Millan, E., additional, Costa, Mário Rui P.F.N., additional, Danquah, Michael K., additional, Das, Biswarup, additional, Dias, Rolando C.S., additional, El Omari, Nasreddine, additional, El-Sherbiny, Ibrahim M., additional, Figueroa-Pizano, M.D., additional, Gomes, Catarina P., additional, Gültekin, Hazal Ezgi, additional, Gupta, Dipak Kumar, additional, Hasnain, Md Saquib, additional, İlhan, Miray, additional, Jain, Sanjay K., additional, Jeevanandam, Jaison, additional, Jha, Abhishek, additional, Kaliyappan, Deviga, additional, Khalid, Shaimaa A., additional, Khan, Abdullah, additional, Kumar, Manish, additional, Laurini, Erik, additional, Mahobia, Swati, additional, Mallick, Subrata, additional, Marson, Domenico, additional, Martins-Gomes, Carlos, additional, Mazhar, Aliza, additional, Mazhar, Maryam, additional, Messina, Paula, additional, Mishra, Brahmeshwar, additional, Misra, Shashi Kiran, additional, Mohamed, Ekram H., additional, Muzammil, Saima, additional, Nayak, Amit Kumar, additional, Pan, Sharadwata, additional, Pathak, Kamla, additional, Pricl, Sabrina, additional, Raikwar, Sarjana, additional, Rençber, Seda, additional, Rodrigues, João, additional, Saini, Rajesh Kumar, additional, Sami, Farheen, additional, Sen, Kalyan Kumar, additional, Shehzad, Mirza Imran, additional, Silva, Amélia M., additional, Souto, Eliana B., additional, Srivastava, Dipti, additional, Torchilin, Vladimir P., additional, Tung, Wai Hau, additional, Waheed, Ayesha, additional, Yeni, Derya Karataş, additional, Zafar, Nimrah, additional, and Şenyiğit, Zeynep, additional

Published
2022
Full Text
View/download PDF

20. List of contributors

Author

Aulic, Suzana, primary, Bharati, Sanjay, additional, Cheruku, Sri Pragnya, additional, Ellederova, Z., additional, Fermeglia, Maurizio, additional, Ghosh, Sougata, additional, Harish Kumar, B., additional, Jadhav, K.M., additional, K.P., Divya, additional, Kamath, Ashwin, additional, Kandasamy, Ganeshlenin, additional, Kanwal, Abhinav, additional, Kanwar, Navjot, additional, Kharat, Prashant B., additional, Khot, Vishwajeet M., additional, Kitture, Rohini, additional, Kumar, Gautam, additional, Kumar, Lalit, additional, Kumar, Nitesh, additional, Lal, Shivakumar Mahadeva, additional, Laurini, Erik, additional, Manandhar, Suman, additional, Mane, Rajaram S., additional, Marson, Domenico, additional, Pai, K. Sreedhara Ranganath, additional, Parida, Amrita, additional, Parihar, Vipan Kumar, additional, Patil, Rakesh M., additional, Pricl, Sabrina, additional, Rao, Vanishree, additional, Rasal, Amol, additional, D. Reddy, Neetinkumar, additional, Rohiwal, S.S., additional, Salunkhe, Ashwini B., additional, Sankhe, Runali, additional, Shenoy, Smita, additional, Shetgaonkar, Gayatri Gopal, additional, Shirsat, Shubhangi D., additional, Singh, Shailendra Pratap, additional, Skoko, Natasa, additional, Somvanshi, Sandeep B., additional, Thorat, Nanasaheb D., additional, Tiwari, A.P., additional, Townley, Helen, additional, U, Anushree, additional, and Vibhavari, R.J.A., additional

Published
2021
Full Text
View/download PDF

23. Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors

Author

Garrigue, Philippe, Tang, Jingjie, Ding, Ling, Bouhlel, Ahlem, Tintaru, Aura, Laurini, Erik, Huang, Yuanyu, Lyu, Zhenbin, Zhang, Mengjie, Fernandez, Samantha, Balasse, Laure, Lan, Wenjun, Mas, Eric, Marson, Domenico, Weng, Yuhua, Liu, Xiaoxuan, Giorgio, Suzanne, Iovanna, Juan, Pricl, Sabrina, Guillet, Benjamin, and Peng, Ling

Published
2018

25. 3D Homology Model of Sigma1 Receptor

Author

Laurini, Erik, Marson, Domenico, Fermeglia, Maurizio, Pricl, Sabrina, Barrett, James E., Editor-in-chief, Flockerzi, Veit, Series editor, Frohman, Michael A., Series editor, Geppetti, Pierangelo, Series editor, Hofmann, Franz B., Series editor, Michel, Martin C., Series editor, Page, Clive P, Series editor, Rosenthal, Walter, Series editor, Wang, KeWei, Series editor, Kim, Felix J., editor, and Pasternak, Gavril W., editor

Published
2017
Full Text
View/download PDF

26. Contributors

Author

Anuje, Madhuri, primary, Aulic, Suzana, additional, Bauer, Joanna, additional, Bhaskaran, Navya Ajitkumar, additional, Burungale, Vishal V., additional, Cabrita, A. Silvério, additional, Chevala, Naga Thirumalesh, additional, Costa, Eduardo, additional, Enrico, Catalano, additional, Fermeglia, Maurizio, additional, Figueiredo, Isabel V., additional, Jadhav, Vijaykumar V., additional, Jagtap, Jaidip M., additional, Kandasamy, Ganeshlenin, additional, Khan, Ahmaduddin, additional, Khot, Vishwajeet M., additional, Kumar, Gautam, additional, Kumar, Koushi, additional, Kumar, Lalit, additional, Kumar, Nitesh, additional, Laurini, Erik, additional, Mane, Rajaram S., additional, Marson, Domenico, additional, Parchur, Abdul K., additional, Patil, Rakesh M., additional, Patil, Sarita P., additional, Pawaskar, P.N., additional, Pricl, Sabrina, additional, Rao, Vanishree, additional, Reis, Catarina P., additional, Rohiwal, Sonali S., additional, Sahu, Niroj Kumar, additional, Salunkhe, Ashwini B., additional, Sharma, Gayatri, additional, Shirsat, Shubhangi D., additional, Sivan, Ajay, additional, Sousa, Alexandra, additional, Thorat, Nanasaheb D., additional, and Tiwari, Arpita Pandey, additional

Published
2020
Full Text
View/download PDF

31. Azacalixphyrin nanostructures

Author

Ferry, Daniel, primary, Pricl, Sabrina, additional, Marson, Domenico, additional, Chen, Zhongrui, additional, Canard, Gabriel, additional, Pascal, Simon, additional, Tintaru, Aura, additional, and Siri, Olivier, additional

Published
2023
Full Text
View/download PDF

34. Transformations of L-DOPA during the synthesis of gold-based nanodelivery systems for LAT-1 targeting

Author

Kalčec, Nikolina, Ljulj, Antonio, Božičević, Lucija, Vrček, Valerije, Marson, Domenico, Pricl, Sabrina, Separovic, Frances, Prassl, Ruth, and Vinković Vrček, Ivana

Subjects
LAT1, gold nanoparticles, L-DOPA, drug-delivery nanosystem
Abstract

LAT-1, the large neutral amino acid transporter-1, plays a crucial role in cancer growth and proliferation, making it a promising biomarker for imaging and treating human malignancies such as brain cancers. Thus, growing attention is being paid to the development of LAT-targeted drug delivery systems with blood-brain penetration ability [1, 2]. For this purpose, gold nanoparticles (AuNPs) functionalized with L-DOPA have been developed [1]. The great potential of such systems to be used in brain cancer therapy prompts the need for evaluation of the processes occurring at the nano-bio interface [3]. In the presence of gold salts, L-DOPA can undergo various transformations such as oxidation, cyclization, and polymerization [4]. To avoid binding structurally altered molecules to the nanosurface and prevent any negative impact on human health, it is important to consider these transformation patterns. This study aimed to investigate the behavior of L-DOPA upon interaction with a gold nanosurface by using a combination of nuclear magnetic resonance (NMR) spectroscopy and computational methods. Experimental results showed that the final form of L-DOPA on the AuNPs surface is dependent on the molar ratio of reactants used during synthesis. When there was an excess of L-DOPA compared to Au, no alterations in the structure of L-DOPA were observed. However, an excess of Au was found to promote the oxidation of L-DOPA, which could result in various oxidation products being bound to the gold nanosurface. NMR spectra revealed that L-DOPA underwent intramolecular cyclization but could not differentiate oxidation products. On the other hand, computational simulations using density functional theory (DFT) and molecular dynamics (MD) techniques identified the most probable oxidation products for binding to the AuNP surface. The highest affinity to gold nanosurface was obtained for dopachrome compared to its tautomer and leukodopachrome. The obtained results represent valuable mechanistic data about the binding events at the surface of AuNPs to encourage their application as a drug-delivery systems in cancer therapy

Published
2023

35. Spotting Local Environments in Self-Assembled Monolayer-Protected Gold Nanoparticles

Author

Gabellini, Cristian, primary, Şologan, Maria, additional, Pellizzoni, Elena, additional, Marson, Domenico, additional, Daka, Mario, additional, Franchi, Paola, additional, Bignardi, Luca, additional, Franchi, Stefano, additional, Posel, Zbyšek, additional, Baraldi, Alessandro, additional, Pengo, Paolo, additional, Lucarini, Marco, additional, Pasquato, Lucia, additional, and Posocco, Paola, additional

Published
2022
Full Text
View/download PDF

38. Contributors

Author

Bradley, Laura C., primary, Bresme, Fernando, additional, Chen, Wei-Han, additional, Cheng, Rui, additional, Deng, Da, additional, Guldin, Stefan, additional, Huang, Weijie, additional, Hubert, Céline, additional, Hueckel, Theodore, additional, Lee, Daeyeon, additional, Liu, Zeke, additional, Ma, Wanli, additional, Ma, Fuduo, additional, Madeira, Alexandra, additional, Mao, Leidong, additional, Marson, Domenico, additional, Posocco, Paola, additional, Ravaine, Serge, additional, Sacanna, Stefano, additional, Salvalaglio, Matteo, additional, Sicard, François, additional, Striolo, Alberto, additional, Tréguer-Delapierre, Mona, additional, Wu, Ning, additional, Yang, Xingfu, additional, Yang, Ye, additional, Ye, Xingchen, additional, Zhao, Yiping, additional, and Zhu, Jian, additional

Published
2018
Full Text
View/download PDF

42. Nanovesicles for the delivery of cardiovascular drugs

Author

Marson, Domenico, Aulic, Suzana, Alice, Fermeglia, Laurini, Erik, Pricl, Sabrina, AK Nayak, MS Hasnain, TM Aminabhavi, VP Torchilin, Marson, Domenico, Aulic, Suzana, Fermeglia, Alice, Laurini, Erik, and Pricl, Sabrina

Subjects
liposomes, slef-assembling nanovectors, cardiovascular disease, Nanovesicular delivery system, liposome, exosome, Nanovesicular delivery systems, cardiovascular diseases, exosomes, nanomedicine, slef-assembling nanovector
Abstract

Cardiovascular diseases (CVDs) are one of the top causes of death on a global scale. According to the World Health Organization (WHO), 17.9 million people die each year as a result of CVDs. With a focus on Europe, 45% of all fatalities in the “old continent”—37% in the European Union (EU) alone—are attributable to CVDs, globally accounting for 3.9 million annual deaths.2 CVD-related diagnosis and treatment expenses increase at a fast rate and are expected to continue to rise in the next decade. As an example, the EU economic burden is estimated to be around 111 billion Euros for the direct costs of CVD treatments annually, with a 210 billion Euro yearly price tag for overall management of CVDs. This impressive economic load is substantially related to an increase in CVD-associated risk factors, which include, among others, obesity, diabetes, and population aging. Although the application of nanomedicine (NM) in the diagnosis and treatment of CVDs is substantially younger than its oncological counterpart, the rapid pace at which it progresses is testified by the number of laboratory-scale results reported, for example, on PubMed (1853 hits returned for the combined cardiovascular1nanomedicine search performed on May 25, 2021—1111 hits only in the last 5 years). From a historical perspective, the majority of the early CVD-directed nanosystems were produced with the aim to improve bioavailability, stability, and safety of medications that were already on the market. Likely, the first successful example in this respect is represented by the proof-ofprinciple study in which lipid-based nanoparticles (NPs) were engineered to revive the clinical potential of the abandoned CVD-targeting compound wortmannin, a potent inhibitor of phosphatidylinositol 30kinase-related kinases that failed clinical translation due solubility and other drug-delivery challenges.4 According to the design, these NPs had a lipid-polymer surface and a hydrophobic polymeric core in which the hydrophobic drug was incapsulated. A lipid monolayer (lecithin and PEGylated lipids [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-amino(polyethylene glycol) (DSPE-PEG)]) was incorporated to stabilizes the NPs, while their surface was decorated with PEG to impart a stealth effect and resists serum protein adsorption and/or opsonization. In combination with drug solubility enhancement, CVD NMs are also expected to (1) protect their therapeutic cargo from systemic degradation, exert reduced toxicity and immunogenicity, be characterized by improved pharmacokinetic/pharmacodynamic profiles and halflife, and be endowed with higher bioavailability and more targeted biodistribution. Notwithstanding the intense research efforts, several technical, ethical and regulatory issues still pose major hurdles along the translational pathway of CVD NMs. This, in turn, accounts for the low number (12) of CVD NMs currently listed in ongoing clinical trials to date and the fact that no NM has been approved for CVD diagnostic/therapeutic purposes both by the United States Food and Drug Administration (FDA) and the European Medicine Agency so far. Among the plethora of NPs designed and produced as NM components, nanovesicles (NVs)—generally defined as self-assembled structures formed by single or multiple concentric bilayers that surround an aqueous core—are widely used in biomedical applications including CVDs.NVs can be both of natural (e.g., exosomes) and synthetic origin (e.g., liposomes), with dimensions ranging from the nanoscale (10^-9 m) to the microscale (10^-6 m). Liposomes, mainly consisting in closed phospholipid bilayers resembling cell membranes in composition, likely are the most popular NVs. Both the chemical and structural features of liposomes largely contributed to their adoption as NVs for drug delivery in many pathologies, including CVDs. Traditional liposomes have been subjected to substantial modifications over the years to improve those physicochemical and biological characteristics deemed critical for drug delivery and diagnostic purposes. Long-circulating (aka stealth), surface-modified, ligand-targeted, and stimuli-responsive liposomes are just a few of the outcomes of these NV modifications. It is important to observe at this point that changes in conventional liposome compositions (such as those briefly outlined earlier) have initiated a process of NV renaming. As a consequence, a Babel of terms—some rather fancy or almost exotic like, for instance, cryptosomes, DQasomes, escheriosomes, niosomes, transfersomes, and many more—began to appear in the relevant scientific literature. As a result, there is an ongoing debate about whether NVs with the suffix “some” in their name can still be considered modified liposomes or must be intended as entirely new entities, and the interested reader is referred to the excellent paper by Apolinario and coworkers for an in-depth view on this subject. According to the same authors, despite the variety of “somes” available, the few approved NVs for clinical use are still referred to as liposomes, and the adoption of this term is reinforced in the relevant final guideline document released by FDA in 2018. From the perspective of natural NVs, exosomes are NVs that have currently received the highest interest, particularly in cancer therapeutics. Exosomes are endosomal-derived extracellular vesicles (ECVs) typically 30 150 nm in diameter, and such dimensions make them the smallest among all ECVs . Delimited by a lipidic bilayer, these NVs are released into the extracellular environment along with their complex cargo derived from the original cell, including signaling molecules, proteins, lipids, and diverse forms of nucleic acids. ECVs populate different body fluids and, due to their ability to carry, transform and exchange their composite molecular load, they contribute to those cell communication mechanisms underlying cellular integrity. Some of the ECV properties like their biocompatibility, modulable targeting efficiency, and high stability render this type of natural NVs remarkable drug delivery vehicles in various diseases, including CVDs. Thus, in this chapter, we focus on liposomes and ECVs as a particular set of NV-based nanodelivery systems (NDSs) in CVDs and will report on some of the most interesting advancements in CVD NV-based therapeutics. These findings will undoubtedly catalyze the efforts of scientists active in this fascinating yet highly challenging field in the near future.

Published
2022

50. Dynamic self-assembling supramolecular dendrimer nanosystems as potent antibacterial candidates against drug-resistant bacteria and biofilms

Author

Dhumal, Dinesh, primary, Maron, Bar, additional, Malach, Einav, additional, Lyu, Zhenbin, additional, Ding, Ling, additional, Marson, Domenico, additional, Laurini, Erik, additional, Tintaru, Aura, additional, Ralahy, Brigino, additional, Giorgio, Suzanne, additional, Pricl, Sabrina, additional, Hayouka, Zvi, additional, and Peng, Ling, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results